Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

21. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion und (...) mirtazapin im vergleich zu weiteren verordnungsfähigen medika-mentösen behandlungen [Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Kosten-nutzen-bewertung von venlafaxin, duloxetin, bupropion

2014 Health Technology Assessment (HTA) Database.

22. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. (PubMed)

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor licensed for the treatment of major depressive disorders, urinary stress incontinence and the management of neuropathic pain associated with diabetic peripheral neuropathy. A number of trials have been conducted to investigate the use of duloxetine in neuropathic and nociceptive painful conditions. This is the first update of a review first published (...) in 2010.To assess the benefits and harms of duloxetine for treating painful neuropathy and different types of chronic pain.On 19th November 2013, we searched The Cochrane Neuromuscular Group Specialized Register, CENTRAL, DARE, HTA, NHSEED, MEDLINE, and EMBASE. We searched ClinicalTrials.gov for ongoing trials in April 2013. We also searched the reference lists of identified publications for trials of duloxetine for the treatment of painful peripheral neuropathy or chronic pain.We selected all

Full Text available with Trip Pro

2014 Cochrane

23. Duloxetine

Duloxetine USE OF DULOXETINE IN PREGNANCY 0344 892 0909 USE OF DULOXETINE IN PREGNANCY (Date of issue: March 2018 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Duloxetine is a serotonin noradrenaline re-uptake inhibitor (SNRI (...) ) indicated for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalised anxiety disorder, and also for the treatment of moderate to severe urinary stress incontinence. There are limited data available on the use of duloxetine in pregnancy, therefore its use would not be routinely recommended. However, where duloxetine is being used effectively prior to conception in the treatment of a maternal psychiatric condition, the risks of destabilisation and maternal relapse

2014 UK Teratology Information Service

24. Duloxetine Lilly

Duloxetine Lilly 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 23 October 2014 EMA/753230/2014 Committee for Medicinal Products for Human Use (CHMP) Duloxetine Lilly duloxetine Procedure No. EMEA/H/C/004000 Applicant: Eli Lilly Nederland B.V. Assessment report for an initial marketing authorisation application Assessment (...) report as adopted by the CHMP with all commercially confidential information deleted Duloxetine Lilly EMA/753230/2014 Page 2/13 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Manufacturers 4 1.3. Steps taken for the assessment of the product 5 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 6 2.3. Non-clinical aspects 6 2.4. Clinical aspects 7 2.5. Pharmacovigilance 7 2.6. Risk Management Plan 7 2.7. Product information 11

2014 European Medicines Agency - EPARs

25. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. (PubMed)

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy.To determine the effect of duloxetine, 60 mg daily, on average pain severity.Randomized, double-blind, placebo-controlled crossover trial at 8 National Cancer Institute (NCI)-funded cooperative research networks that enrolled 231 patients who (...) were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10

Full Text available with Trip Pro

2013 JAMA

26. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Executive Summary 1 Translation of the executive summary of the final report “Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen” (Version 1.0; Status: 3 September 2013). Please note: This translation is provided as a service by IQWiG to English-language (...) readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. G09-01 Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments 1 Executive summary of final report G09-01 Version 1.0 Health economic evaluation of venlafaxine, duloxetine, bupropion, mirtazapine 3 Sep 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

27. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial (PubMed)

Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial pain is the leading symptom of osteoarthritis (OA) and is often chronic in nature, leading to significant morbidity and decreased quality of life. Duloxetine, a selective serotonin norepinephrine reuptake inhibitor has been demonstrated to have a centrally acting analgesic effect.the aim of the present study was to investigate the efficacy of duloxetine in reducing pain in older (...) adults with knee OA.totally, 288 patients aged 65 years and above with primary knee OA were enrolled in this study. Patients were randomised 1:1. Totally, 144 received 60 mg/day of duloxetine HCL and 144 received placebo for 16 weeks. Outcome measures included pain reduction and improvement in physical functioning scores. Pain was assessed using the visual analogue pain scale (VAS; 0-100 mm). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were used to assess

Full Text available with Trip Pro

2012 EvidenceUpdates

28. Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States

Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States Beard SM, Roskell N, Le TK, Zhao Y, Coleman A, Ang D, Lawson K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of duloxetine for the treatment of moderate-to-severe pain from fibromyalgia. It focused on the best position for duloxetine in the treatment sequence. The authors concluded that adding duloxetine to the treatment sequence for fibromyalgia was cost-effective, particularly when it was the second-line treatment after

2012 NHS Economic Evaluation Database.

29. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data

A systematic review of duloxetine and venlafaxine in major depression, including unpublished data Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

30. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico

Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Carlos F, Ramirez-Gamez J, Duenas H, Galindo-Suarez RM, Ramos E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of duloxetine as a first treatment for adults with diabetic peripheral neuropathy and moderate-to-severe pain. The authors concluded that duloxetine was a cost-effective intervention, in Mexico. Overall, the study was adequate

2012 NHS Economic Evaluation Database.

31. A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: A randomized, double-blind, cross-over clinical trial (PubMed)

A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: A randomized, double-blind, cross-over clinical trial To compare the efficacy and safety of duloxetine and amitriptyline in painful diabetic neuropathy (PDN).In this randomized, double-blind, cross-over, active-control trial, 58 patients received amitriptyline and duloxetine orally once daily at bedtime, each for 6 weeks with optional dose uptitration fortnightly. Single-blinded placebo washout was given (...) improvement in pain with both treatments compared with their baseline values (P < 0.001 for both). Good, moderate, and mild pain relief was achieved in 55, 24, and 15% of patients, respectively, on amitriptyline and 59, 21, and 9% of patients, respectively, on duloxetine. There were no significant differences in various other outcome measures between the groups. Of the reported adverse events, dry mouth was significantly more common with amitriptyline than duloxetine (55 vs. 24%; P < 0.01). Although

Full Text available with Trip Pro

2011 EvidenceUpdates

32. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis (PubMed)

Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis To evaluate and compare the efficacy and acceptability of the antidepressants amitriptyline (AMT), duloxetine (DLX) and milnacipran (MLN) for FM syndrome (FMS).Cochrane Library, MEDLINE, SCOPUS, www.clinicalstudyresults.org and www.clinicalTrials.gov were searched for randomized pharmacological placebo-controlled trials until 30 May 2010. Outcomes

Full Text available with Trip Pro

2011 EvidenceUpdates

33. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine (PubMed)

Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine The objective of this paper is to better understand the relationship of pain and mood in patients with fibromyalgia and comorbid major depressive disorder (MDD). Pooled data from 4 double-blind, placebo-controlled, randomized trials of duloxetine hydrochloride 60-120mg/day in patients with fibromyalgia were included (...) (N=1332). Of these, 350 (26% [147 placebo, 203 duloxetine]) had comorbid MDD (per Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria) and were included in these analyses. Primary measures included Brief Pain Inventory average pain; Hamilton Depression Rating Scale or Beck Depression Inventory. Logistic regression was used to evaluate the consistency of treatment effect across various subgroups. Path analysis was used to assess the effect of duloxetine

2011 EvidenceUpdates

34. Pain response profile of patients with fibromyalgia treated with duloxetine (PubMed)

Pain response profile of patients with fibromyalgia treated with duloxetine This study examined the time course for minimal clinically significant improvement in pain severity during the initial 12 weeks of treatment in patients with fibromyalgia taking duloxetine.Four double-blind, placebo-controlled trials of duloxetine were pooled. Patients received duloxetine 60 mg/d, 120 mg/d, or placebo. Clinically significant treatment response (>or=30% reduction in pain severity on the 24-hour average (...) pain severity of the Brief Pain Inventory scale) was assessed over 12 weeks.At endpoint, 46.9% of duloxetine 60-mg-, 48.6% of duloxetine 120-mg-, and 32.1% of placebo-treated patients (P<0.001 for both doses) had >or=30% improvement on average pain from baseline. The probabilities of achieving >or=30% response at Weeks 1, 2, 4, 8, and 12 among duloxetine 60-mg-treated patients were 27%, 44%, 45%, 47%, and 49%, respectively, and among duloxetine 120-mg-treated patients were 35%, 43%, 53%, 53

2010 EvidenceUpdates

35. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome (PubMed)

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Duloxetine (DLX), milnacipran (MLN), and pregabalin (PGB) are the only drugs licensed by the US Food and Drug Administration (FDA) for fibromyalgia syndrome (FMS). Evidence on the comparative benefits and harms is still accruing. The authors searched MEDLINE, SCOPUS, Cochrane Central Register of Controlled Trials, and sought unpublished data from the databases of FDA, US National Institutes (...) ) efficacy of DLX, MLN, and PGB. Differences with regard to the occurrence of the key symptoms of FMS and to drug-specific adverse events may be relevant for the choice of medication.This article presents comparative data on the efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. The results can help clinicians in choosing medication since the 3 drugs have different effects on the key symptoms of fibromyalgia syndrome and differences in side effects, contraindications

2010 EvidenceUpdates

36. Cymbalta (duloxetine hydrochloride)

Cymbalta (duloxetine hydrochloride) Drug Approval Package: Cymbalta (duloxetine hydrochloride) NDA #022516 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Cymbalta (duloxetine hydrochloride), 20, 30, and 60 mg Capsules Company: Eli Lilly and Company Application No.: 022516 Approval Date: 11/04/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

37. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Benedict A, Arellano J, De Cock E, Baird J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-utility of duloxetine, compared with selective serotonin re-uptake inhibitors (SSRIs), venlafaxine extended release, and mirtazapine, for the treatment of major

2010 NHS Economic Evaluation Database.

38. Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence

Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Jacklin P, Duckett J, Renganathan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of duloxetine versus tension-free vaginal tape as the second-line treatment for urinary stress incontinence, using new data on drug discontinuation rates. The authors concluded that tension-free vaginal tape was more cost-effective than duloxetine and was below the recommended

2010 NHS Economic Evaluation Database.

39. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Hauser W, Petzke F, Sommer C CRD summary The authors concluded that there was evidence of the short-term (up to six months) efficacy of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome (...) ; the drugs differed in their effects on fibromyalgia syndrome domains and side-effects. The conclusions about the relative efficacy of drugs were not based on direct comparisons and may not be definitive. Authors' objectives To compare the efficacy and side-effects of duloxetine, milnacipran and pregabalin for the treatment of fibromyalgia syndrome. Searching MEDLINE, SCOPUS and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to May 2009. Information was provided about the search

2010 DARE.

40. Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study

Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Mihaylova B, Pitman R, Tincello D, van der Vaart H, Tunn R, Timlin L, Quail D, Johns A, Sculpher M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of duloxetine compared with conservative therapy for women with stress urinary incontinence. The authors concluded that, although there were limitations due to the use of observational data, duloxetine therapy seemed to be cost-effective. The methods were good

Full Text available with Trip Pro

2010 NHS Economic Evaluation Database.